8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 11, 2026·SEC
biote Corp.(BTMD)Earnings, Financials & Key Ratios
BTMD•NASDAQ
$2.25
3.0× P/E·Price updated Jul 7, 2026
Aboutbiote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.Show more
- Revenue$192M-2.5%
- EBITDA$39M+11.5%
- Net Income$27M+756.7%
- EPS (Diluted)0.74+703.5%
- Gross Margin71.46%+1.3%
- EBITDA Margin20.4%+14.4%
- Operating Margin18.5%+15.4%
- Net Margin14.07%+778.8%
BTMD Price & Volume
biote Corp. (BTMD) stock price & volume — 10-year historical chart
Loading chart...
Contracting Revenue Growth Masks Structural Solvency Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Moderate
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Regulatory compounding supply disruption
Key Thesis Takeaways
- Biote Corp.
- faces a challenging outlook characterized by persistent revenue contraction, which fell 8.3% YoY in 2026Q1, and a deteriorating balance sheet with negative equity of $56.1 million.
- While the company maintains resilient gross margins of 68.9%, the lack of consistent operating leverage and a rapid depletion of cash reserves from $89.0 million in 2023Q4 to $5.3 million in 2026Q1 create significant execution risk.
- Investors should monitor the company's ability to stabilize its practitioner network and manage its $108.4 million debt load amidst ongoing operational volatility.
Verdict Logic
the company's rapid cash depletion to $5.3 million and persistent negative equity of $56.1 million present substantial solvency risks that outweigh the current 2.42 P/E valuation.
BTMD Growth Metrics
biote Corp. (BTMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years10.52%
3 Years5.23%
TTM-5.63%
Profit CAGR
10 Years-
5 Years-1.5%
3 Years-
TTM-28.43%
EPS CAGR
10 Years-
5 Years-28.1%
3 Years66.61%
TTM-27.23%
Return on Capital
10 Years80.8%
5 Years27.11%
3 Years36.54%
Last Year53.27%
BTMD Recent Earnings
biote Corp. (BTMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.06-33.3%
$0.09
Rev
$45M-2.4%
$46M
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.06+20.0%
$0.05
Rev
$46M+1.3%
$46M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.22+340.0%
$0.05
Rev
$48M+4.7%
$46M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.10+66.7%
$0.06
Rev
$49M+2.3%
$48M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.06vs $0.09-33.3% | $45Mvs $46M-2.4% |
| Q2 2026 | Mar 11, 2026 | $0.06vs $0.05+20.0% | $46Mvs $46M+1.3% |
| Q4 2025 | Nov 5, 2025 | $0.22vs $0.05+340.0% | $48Mvs $46M+4.7% |
| Q3 2025 | Aug 6, 2025 | $0.10vs $0.06+66.7% | $49Mvs $48M+2.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for biote Corp. (BTMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.25 | $99.24M | 3.04 | -2.52% | 14.07% | — | 2.09% | |
| $36.17 | $7.94B | 70.92 | 59% | -0.56% | -2.48% | — | |
| $3.31 | $20.91M | -2.74 | 125.12% | -102.42% | -61.46% | — | |
| $8.99 | $150.21M | -1.51 | -1.98% | -48.16% | -33.48% | — | |
| $5.67 | $1.97B | -9.45 | 698.96% | -102.06% | -44.1% | — | |
| $3.03 | $1.05B | 35.52 | 0.57% | 3.74% | 4.75% | — |
Compare BTMD vs Peers
biote Corp. (BTMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BTMD SEC Filings & Documents
biote Corp. (BTMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BTMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BTMD Frequently Asked Questions
biote Corp. (BTMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is biote Corp.'s revenue?
biote Corp. (BTMD) reported $188.2M in revenue for fiscal year 2025. This represents a 71% increase from $110.0M in 2019.
How fast is biote Corp. growing?
biote Corp. (BTMD) saw revenue decline by 2.5% over the past year.
Is BTMD profitable?
Yes, biote Corp. (BTMD) is profitable, generating $15.6M in net income for fiscal year 2025 (14.1% net margin).
Dividend & Returns
Does BTMD pay dividends?
Yes, biote Corp. (BTMD) pays a dividend with a yield of 2.09%. This makes it attractive for income-focused investors.
What is biote Corp.'s free cash flow?
biote Corp. (BTMD) generated $28.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.